GBIO Stock Overview
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Generation Bio Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.42 |
| 52 Week High | US$9.59 |
| 52 Week Low | US$3.55 |
| Beta | 1.6 |
| 1 Month Change | 26.38% |
| 3 Month Change | 7.72% |
| 1 Year Change | 10.31% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.00% |
Recent News & Updates
Recent updates
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans
Nov 19
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely
Aug 05Generation Bio GAAP EPS of -$0.66 misses by $0.04
Aug 04Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth
Apr 20Generation Bio: High-Risk, Medium-To-Low-Reward
Dec 30We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Nov 11We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth
Jul 28Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Mar 08Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares
Jan 14
Generation Bio's insiders on buying spree, stock +4%
Jan 13Generation Bio prices equity offering at $24.50
Jan 07Generation Bio files to offer 7.5M shares
Jan 04Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?
Dec 27Generation Bio EPS misses by $0.01
Nov 10Shareholder Returns
| GBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.1% | -0.8% | 2.9% |
| 1Y | 10.3% | 4.5% | -8.5% |
Return vs Industry: GBIO exceeded the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: GBIO exceeded the US Market which returned -9.1% over the past year.
Price Volatility
| GBIO volatility | |
|---|---|
| GBIO Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: GBIO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: GBIO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 150 | Geoff McDonough | https://generationbio.com |
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
Generation Bio Co. Fundamentals Summary
| GBIO fundamental statistics | |
|---|---|
| Market Cap | US$381.49m |
| Earnings (TTM) | -US$135.18m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs GBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$135.18m |
| Earnings | -US$135.18m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GBIO perform over the long term?
See historical performance and comparison